Novel ω-conotoxins from C. catus reverse signs of mouse inflammatory pain after systemic administration

11Citations
Citations of this article
29Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Antagonists of N-type voltage-gated calcium channels (VGCC), Cav2.2, can manage severe chronic pain with intrathecal use and may be effective systemically. A series of novel ω-conotoxins that selectively inhibit N-type VGCCs was isolated from Conus catus. In the present study, the potency and reversibility of ω-conotoxins CVID, CVIE and CVIF to inhibit N-type calcium currents were investigated in mouse isolated dorsal root ganglion (DRG) neurons. The systemic potency of each ω-conotoxin to reverse signs of mouse chronic inflammatory pain was also compared. Results:In DRG neurons, the rank order of potency to inhibit N-type calcium currents was CVIE > CVIF > CVID. After subcutaneous administration, CVID and CVIE, but not CVIF, partially reversed impaired weight bearing in mice injected with Freund's complete adjuvant (CFA) three days prior to testing. No side-effects associated with systemic administration of ω-conotoxins were observed. Conclusions: The present study indicates a potential for CVID and CVIE to be developed as systemically active analgesics with no accompanying neurological side-effects. © 2013 Sadeghi et al.; licensee BioMed Central Ltd.

Cite

CITATION STYLE

APA

Sadeghi, M., Murali, S. S., Lewis, R. J., Alewood, P. F., Mohammadi, S., & Christie, M. J. (2013). Novel ω-conotoxins from C. catus reverse signs of mouse inflammatory pain after systemic administration. Molecular Pain, 9(1). https://doi.org/10.1186/1744-8069-9-51

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free